A Randomized Parallel Controlled Phase II Trial of Recombinant Human Endostatin Added to Neoadjuvant Chemotherapy for Stage III Breast Cancer

Xiangmei Zhang; Zhenzhen Zhang; Miao Cao; Beichen Liu; Motomi Mori; Shiuh Wen Luoh; Raymond Bergan; Yueping Liu; Yunjiang Liu

doi:10.1016/j.clbc.2020.04.009

A Randomized Parallel Controlled Phase II Trial of Recombinant Human Endostatin Added to Neoadjuvant Chemotherapy for Stage III Breast Cancer

Xiangmei Zhang
, Zhenzhen Zhang
, Miao Cao
, Beichen Liu
, Motomi Mori
, Shiuh Wen Luoh
, Raymond Bergan
, Yueping Liu
, Yunjiang Liu

Cancer Center

Hebei Medical University
OHSU-PSU School of Public Health
St. Jude Children Research Hospital
Oregon Health and Science University

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

This clinical trial evaluated recombinant human endostatin in breast cancer neoadjuvant chemotherapy. Eighty-seven patients with stage III breast cancer randomly received 4 cycles neoadjuvant of TEC (docetaxel, epirubicin, and cyclophosphamide) or recombinant human endostatin + TEC, followed by surgery. The latter significantly improved the overall survival, suggesting a benefit of adding anti-angiogenesis to standard chemotherapy in the treatment of breast cancer.

Original language	English
Pages (from-to)	291-299.e3
Journal	Clinical Breast Cancer
Volume	20
Issue number	4
DOIs	https://doi.org/10.1016/j.clbc.2020.04.009
State	Published - Aug 2020

Keywords

Breast cancer
Neoadjuvant therapy
Objective response rate
Overall survival
Recombinant human endostatin

Access to Document

10.1016/j.clbc.2020.04.009

Cite this

@article{ac5804586468421d91209127418adcc9,

title = "A Randomized Parallel Controlled Phase II Trial of Recombinant Human Endostatin Added to Neoadjuvant Chemotherapy for Stage III Breast Cancer",

abstract = "This clinical trial evaluated recombinant human endostatin in breast cancer neoadjuvant chemotherapy. Eighty-seven patients with stage III breast cancer randomly received 4 cycles neoadjuvant of TEC (docetaxel, epirubicin, and cyclophosphamide) or recombinant human endostatin + TEC, followed by surgery. The latter significantly improved the overall survival, suggesting a benefit of adding anti-angiogenesis to standard chemotherapy in the treatment of breast cancer.",

keywords = "Breast cancer, Neoadjuvant therapy, Objective response rate, Overall survival, Recombinant human endostatin",

author = "Xiangmei Zhang and Zhenzhen Zhang and Miao Cao and Beichen Liu and Motomi Mori and Luoh, \{Shiuh Wen\} and Raymond Bergan and Yueping Liu and Yunjiang Liu",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2020",

month = aug,

doi = "10.1016/j.clbc.2020.04.009",

language = "English",

volume = "20",

pages = "291--299.e3",

journal = "Clinical Breast Cancer",

issn = "1526-8209",

number = "4",

}

TY - JOUR

T1 - A Randomized Parallel Controlled Phase II Trial of Recombinant Human Endostatin Added to Neoadjuvant Chemotherapy for Stage III Breast Cancer

AU - Zhang, Xiangmei

AU - Zhang, Zhenzhen

AU - Cao, Miao

AU - Liu, Beichen

AU - Mori, Motomi

AU - Luoh, Shiuh Wen

AU - Bergan, Raymond

AU - Liu, Yueping

AU - Liu, Yunjiang

PY - 2020/8

Y1 - 2020/8

N2 - This clinical trial evaluated recombinant human endostatin in breast cancer neoadjuvant chemotherapy. Eighty-seven patients with stage III breast cancer randomly received 4 cycles neoadjuvant of TEC (docetaxel, epirubicin, and cyclophosphamide) or recombinant human endostatin + TEC, followed by surgery. The latter significantly improved the overall survival, suggesting a benefit of adding anti-angiogenesis to standard chemotherapy in the treatment of breast cancer.

AB - This clinical trial evaluated recombinant human endostatin in breast cancer neoadjuvant chemotherapy. Eighty-seven patients with stage III breast cancer randomly received 4 cycles neoadjuvant of TEC (docetaxel, epirubicin, and cyclophosphamide) or recombinant human endostatin + TEC, followed by surgery. The latter significantly improved the overall survival, suggesting a benefit of adding anti-angiogenesis to standard chemotherapy in the treatment of breast cancer.

KW - Breast cancer

KW - Neoadjuvant therapy

KW - Objective response rate

KW - Overall survival

KW - Recombinant human endostatin

UR - https://www.scopus.com/pages/publications/85085607633

U2 - 10.1016/j.clbc.2020.04.009

DO - 10.1016/j.clbc.2020.04.009

M3 - Article

C2 - 32482525

AN - SCOPUS:85085607633

SN - 1526-8209

VL - 20

SP - 291-299.e3

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

IS - 4

ER -

A Randomized Parallel Controlled Phase II Trial of Recombinant Human Endostatin Added to Neoadjuvant Chemotherapy for Stage III Breast Cancer

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this